Table 1.
Sample-based eccDNA catalogue.
| SRA | Status | eccDNA | Percentage of cells harboring eccDNA |
|---|---|---|---|
| SRR10315835 | Adult primary glioblastoma tissue | chr1:143184615–143275868; chr10:41843349–41916253; chr16:34571510–34576756; chr17:21968723–21991976; chr2:89825156–89841143; chr20:31051578–31076467; chr4:49091284–49157869; chr4:49631387–49658060; chr5:49599456–49603119; chr5:49656346–49661867; chr6:157310412–157315333; chrY:11323910–11331672; chrY:56673236–56771486 | 9.96% |
| SRR10315836 | Adult primary glioblastoma tissue | chr1:143184614–143275894; chr1:2652118–2684542; chr10:41843212–41916258; chr16:34571503–34576757; chr17:21967556–21991976; chr17:314519–317065; chr2:89823883–89841143; chr20:31051537–31077112; chr21:10700507–10739583; chr3:93470352–93470800; chr4:49091262–49158469; chr4:49631349–49658068; chr4:49709089–49711938; chr5:49599427–49603116; chr5:49656342–49661867; chrY:56822743–56851689 |
15.19% |
| SRR10315837 | Adult primary glioblastoma tissue | chr1:143184612–143275983; chr1:2682915–2694403; chr10:41843231–41916263; chr16:34571506–34576757; chr16:46380677–46401941; chr17:21968716–21991986; chr2:739827–741112; chr2:89825266–89842856; chr2:91497291–91528777; chr20:31051537–31077274; chr21:10695714–10738318; chr21:8376529–8472351; chr22:10711132–10736488; chr4:49091252–49157869; chr4:49631351–49658067; chr4:49709089–49711943; chr5:178585437–178585743; chr5:49599405–49603122; chr5:49656346–49661870; chr6:157310364–157315164; chr8:144767333–144768654; chrY:11290910–11306500 |
13.96% |
| SRR10315838 | Adult primary glioblastoma tissue | chr1:143184610–143275984; chr10:41843002–41916248; chr16:34571510–34576756; chr17:21968723–21991977; chr2:89823776–89841183; chr20:31051539–31077009; chr3:93470352–93470800; chr4:49091250–49157181; chr4:49631364–49658068; chr5:49656350–49661870; chrY:56673233–56771492 | 15.71% |
| SRR13282530 | Patient-derived pediatric glioblastoma tissue (relapse) | chr1:143184614–143275951; chr10:41843226–41916248; chr17:21968743–21991975; chr2:90380639–90402452; chr20:31051540–31076465; chr4:49091289–49156577; chr4:49631401–49658065; chr5:49656348–49661868 | 9.20% |
| SRR13282531 | Patient-derived pediatric glioblastoma tissue (relapse) | chr10:41857290–41916225; chr17:21968781–21991569; chr2:739916–741331; chr2:89826160–89841128; chr20:31051563–31076456; chr4:49091302–49156541; chr4:49631408–49658048; chr5:49656348–49661857; chr6:157310421–157315382; chr8:144766838–144768598; chrY:56828779–56840003 |
10.11% |
| SRR13282532 | Patient-derived pediatric glioblastoma tissue (relapse) | chr1:143260441–143268678; chr10:41857287–41871986; chr10:41873065–41915909; chr17:21968778–21991897; chr17:43231332–43301937; chr2:89826161–89841128; chr20:31051539–31076455; chr4:49091387–49121313; chr4:49122351–49156537; chr4:49631407–49658048; chr4:49709167–49711912; chr5:49599433–49603099; chr6:157310423–157315436; chr8:144767275–144768500 | 8.79% |
| SRR13320479 | Primary patient-derived pediatric glioblastoma | chr1:143184612–143275986; chr10:41843027–41916258; chr10:42066290–42105009; chr16:34571510–34576756; chr17:21968718–21991987; chr2:89824986–89841138; chr20:31051537–31077112; chr4:49091264–49158471; chr4:49631342–49658068; chr5:178585544–178586817; chr5:49599412–49603119; chr5:49656341–49661870; chrY:11289953–11306514; chrY:56673229–56771494; chrY:56825444–56851466 | 14.51% |
| SRR13320481 | Primary patient-derived pediatric glioblastoma | chr10:41873325–41881847; chr20:31051592–31060773; chr20:31061789–31069767; chr4:49091369–49112948; chr5:49656411–49661832; chr8:144761069–144768723 | 2.56% |